Phase I clinical trial in patients with recurrent gliomas: delta-24-RGD oncolytic adenovirus induces an antiglioma immune-response

被引：0
|
作者：
Fueyo, J. [1 ]
Gomez-Manzano, C. [1 ]
Conrad, C. [1 ]
Heimberger, A. [1 ]
Vence, L. [1 ]
Aldape, K. [1 ]
Yung, W. A. [1 ]
Sawaya, R. [1 ]
Fuller, G. [1 ]
Lang, F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] Oncolytic adenovirus delta-24-RGD induces efficacious antiglioma activity in brain tumor stem cell models
    Jiang, Hong
    Gomez-Manzano, Candelaria
    Yokoyama, Tomohisa
    Alonso, Marta
    Kondo, Seiji
    Xu, Jing
    Bekele, B. Nebiyou
    Colman, Howard
    Lang, Frederick
    Fueyo, Juan
    [J]. NEURO-ONCOLOGY, 2007, 9 (04) : 496 - 496
  • [2] IMMUNOMARKERS IN THE DNX-2401 (DELTA-24-RGD) ONCOLYTIC VIRUS PHASE I CLINICAL TRIAL
    Fueyo, Juan
    Gomez-Manzano, Candelaria
    Villalobos, Paloma
    Rodriguez-Canales, Jaime
    Wistuba, Ignacio
    Hess, Kenneth R.
    Alonso, Marta M.
    Tejada, Sonia
    Valle, Ricardo Diez
    Ewald, Brett
    Tufaro, Frank
    Lang, Fred
    [J]. NEURO-ONCOLOGY, 2017, 19 : 27 - 27
  • [3] Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy
    Gonzalez-Morales, Andrea
    Zabaleta, Aintzane
    Garcia-Moure, Marc
    Alonso, Marta M.
    Fernandez-Irigoyen, Joaquin
    Stamaria, Enrique
    [J]. JOURNAL OF PROTEOMICS, 2019, 194 : 168 - 178
  • [4] A CHIMERIC ONCOLYTIC ADENOVIRUS CIRCUMVENTS NEUTRALIZING ANTIBODIES DEVELOPED BY PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH DELTA-24-RGD
    Shin, Dong Ho
    Jiang, Hong
    Gillard, Andrew
    Fan, Xuejun
    Singh, Sanjay
    Lopez-Rivas, Andres
    He, Jiasen
    Gumin, Joy
    Lang, Frederick
    Gomez-Manzano, Candelaria
    Fueyo-Margareto, Juan
    [J]. NEURO-ONCOLOGY, 2023, 25
  • [5] Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
    Lang, Frederick F.
    Conrad, Charles
    Gomez-Manzano, Candelaria
    Yung, W. K. Alfred
    Sawaya, Raymond
    Weinberg, Jeffrey S.
    Prabhu, Sujit S.
    Rao, Ganesh
    Fuller, Gregory N.
    Aldape, Kenneth D.
    Gumin, Joy
    Vence, Luis M.
    Wistuba, Ignacio
    Rodriguez-Canales, Jaime
    Villalobos, Pamela A.
    Dirven, Clemens M. F.
    Tejada, Sonia
    Valle, Ricardo D.
    Alonso, Marta M.
    Ewald, Brett
    Peterkin, Joanna J.
    Tufaro, Frank
    Fueyo, Juan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) : 1419 - +
  • [6] THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD INDUCES A POTENT ANTITUMOR EFFECT IN VITRO AND IN VIVO IN PEDIATRIC OSTEOSARCOMA
    Patino-Garcia, Ana
    Marrodan, Lucia
    Jauregui, Patricia
    Toledo, Gemma
    Zandueta, Carolina
    Xipell, Enric
    Urquiza, Leyre
    Sierrasesumaga, Luis
    Zalacain, Marta
    Lecanda, Fernando
    Alonso, Marta M.
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1050 - 1050
  • [7] GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory
    Rivera-Molina, Yisel
    Jiang, Hong
    Fueyo, Juan
    Nguyen, Teresa
    Shin, Dong Ho
    Youssef, Gilbert
    Fan, Xuejun
    Gumin, Joy
    Alonso, Marta M.
    Phadnis, Sheetal
    Lang, Frederick F.
    Gomez-Manzano, Candelaria
    [J]. NEURO-ONCOLOGY ADVANCES, 2019, 1 (01)
  • [8] Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
    van Putten, Erik H. P.
    Kleijn, Anne
    van Beusechem, Victor W.
    Noske, David
    Lamers, Cor H. J.
    de Goede, Anna L.
    Idema, Sander
    Hoefnagel, Daphna
    Kloezeman, Jenneke J.
    Fueyo, Juan
    Lang, Frederick F.
    Teunissen, Charlotte E.
    Vernhout, Rene M.
    Bakker, Cathy
    Gerritsen, Winald
    Curiel, David T.
    Vulto, Arnold
    Lamfers, Martine L. M.
    Dirven, Clemens M. F.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1572 - 1585
  • [9] Phase I Clinical Trial of Oncolytic Delta-24-RGD (DNX-2401) with Biological Endpoints: Implications for Viro-Immunotherapy
    Lang, Frederick F., Jr.
    Conrad, Charles
    Gomez-Manzano, Candelaria
    Tufaro, Frank
    Sawaya, Raymond
    Weinberg, Jeffrey
    Prabhu, Sujit
    Fuller, Gregory
    Aldape, Kenneth
    Fueyo, Juan
    [J]. JOURNAL OF NEUROSURGERY, 2015, 123 (02) : A486 - A486
  • [10] Preliminary results of the phase 1 trial with the Delta24RGD oncolytic adenovirus, administered by CED in patients with recurrent Glioblastoma
    Dirven, Clemens M. F.
    [J]. HUMAN GENE THERAPY, 2014, 25 (11) : A20 - A20
12345